Lipoprotein subclass metabolism in nonalcoholic steatohepatitis

Journal of Lipid Research

Volumn 55, Issue 12, 2014, Pages 2676-2684

  Männistö, Ville T ^a   Simonen, Marko ^a   Soininen, Pasi ^a,b   Tiainen, Mika ^a   Kangas, Antti J ^b   Kaminska, Dorota ^a   Venesmaa, Sari ^a   Käkelä, Pirjo ^a   Kärjä, Vesa ^a   Gylling, Helena ^a,c   Ala Korpela, Mika ^a,b,d,e   Pihlajamäki, Jussi ^a,f  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

High density lipoprotein; Lipids; Lipoproteins metabolism; Liver; Low density lipoprotein; Nuclear magnetic resonance; Obesity; Obesity surgery; Very low density lipoprotein

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; LIPID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BODY MASS; CELL DAMAGE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL LIVER LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FIBROSIS; GAS CHROMATOGRAPHY; GENE EXPRESSION; GENOTYPE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIQUID CHROMATOGRAPHY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBID OBESITY; NONALCOHOLIC FATTY LIVER; PROTON NUCLEAR MAGNETIC RESONANCE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; FINLAND; HYPERLIPIDEMIAS; IMMUNOLOGY; LIVER; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID; PATHOLOGY; PATHOPHYSIOLOGY; STOMACH BYPASS; UNIVERSITY HOSPITAL;

ADULT; BODY MASS INDEX; CHOLESTEROL; CHOLESTEROL, VLDL; FEMALE; FINLAND; GASTRIC BYPASS; HOSPITALS, UNIVERSITY; HUMANS; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY, MORBID;

EID: 84919941318     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P054387     Document Type: Article

References (46)

1. Musso, G., R. Gambino, and M. Cassader. 2010. Non-alcoholic fatty liver disease from pathogenesis to management: an update. Obes. Rev. 11: 430-445.
2. Vernon, G., A. Baranova, and Z. M. Younossi. 2011. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34: 274-285.
3. Browning, J. D., and J. D. Horton. 2004. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 114: 147-152.
4. Adiels, M., M. R. Taskinen, C. Packard, M. J. Caslake, A. Soro-Paavonen, J. Westerbacka, S. Vehkavaara, A. Hakkinen, S. O. Olofsson, H. Yki-Jarvinen, et al. 2006. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia. 49: 755-765.
5. Kotronen, A., and H. Yki-Järvinen. 2008. Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28: 27-38.
6. Ekstedt, M., L. E. Franzen, U. L. Mathiesen, L. Thorelius, M. Holmqvist, G. Bodemar, and S. Kechagias. 2006. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 44: 865-873.
7. Fabbrini, E., B. S. Mohammed, F. Magkos, K. M. Korenblat, B. W. Patterson, and S. Klein. 2008. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 134: 424-431.
8. Simonen, P., A. Kotronen, M. Hallikainen, K. Sevastianova, J. Makkonen, A. Hakkarainen, N. Lundbom, T. A. Miettinen, H. Gylling, and H. Yki-Järvinen. 2011. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J. Hepatol. 54: 153-159.
9. Puri, P., R. A. Baillie, M. M. Wiest, F. Mirshahi, J. Choudhury, O. Cheung, C. Sargeant, M. J. Contos, and A. J. Sanyal. 2007. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 46: 1081-1090.
10. Kotronen, A., J. Westerbacka, R. Bergholm, K. H. Pietiläinen, and H. Yki-Järvinen. 2007. Liver fat in the metabolic syndrome. J. Clin. Endocrinol. Metab. 92: 3490-3497.
11. Alkhouri, N., T. A. Tamimi, L. Yerian, R. Lopez, N. N. Zein, and A. E. Feldstein. 2010. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk. Dig. Dis. Sci. 55: 2644-2650.
12. Koruk, M., M. C. Savas, O. Yilmaz, S. Taysi, M. Karakok, C. Gundogdu, and A. Yilmaz. 2003. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 37: 177-182.
13. Soininen, P., A. J. Kangas, P. Wurtz, T. Tukiainen, T. Tynkkynen, R. Laatikainen, M. R. Järvelin, M. Kähönen, T. Lehtimäki, J. Viikari, et al. 2009. High-throughput serum NMR metabonomics for costeffective holistic studies on systemic metabolism. Analyst. 134: 1781-1785.
14. Pihlajamäki, J., S. Grönlund, M. Simonen, P. Käkelä, L. Moilanen, M. Pääkkönen, E. Pirinen, M. Kolehmainen, V. Kärjä, S. Kainulainen, et al. 2010. Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after gastric banding. Metabolism. 59: 866-872.
15. Pihlajamäki, J., T. Kuulasmaa, D. Kaminska, M. Simonen, V. Kärjä, S. Grönlund, P. Käkelä, M. Pääkkönen, S. Kainulainen, K. Punnonen, et al. 2012. Serum interleukin 1 receptor antagonist as an independent marker of nonalcoholic steatohepatitis in humans. Int. J. Hepatol. 56: 663-670.
16. Alberti, K. G., and P. Z. Zimmet. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15: 539-553.
17. Ala-Korpela, M. 2008. Critical evaluation of 1H NMR metabonomics of serum as a methodology for disease risk assessment and diagnostics. Clin. Chem. Lab. Med. 46: 27-42.
18. Ala-Korpela, M., P. Soininen, and M. J. Savolainen. 2009. Letter by Ala-Korpela et al. regarding article, "Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women". Circulation. 120: e149.
19. Inouye, M., J. Kettunen, P. Soininen, K. Silander, S. Ripatti, L. S. Kumpula, E. Hämäläinen, P. Jousilahti, A. J. Kangas, S. Männistö, et al. 2010. Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol. Syst. Biol. 6: 441.
20. Tukiainen, T., J. Kettunen, A. J. Kangas, L. P. Lyytikäinen, P. Soininen, A. P. Sarin, E. Tikkanen, P. F. O'Reilly, M. J. Savolainen, K. Kaski, et al. 2012. Detailed metabolic and genetic characterization reveals new associations for 30 known lipid loci. Hum. Mol. Genet. 21: 1444-1455.
21. Chambers, J. C., W. Zhang, J. Sehmi, X. Li, M. N. Wass, P. Van der Harst, H. Holm, S. Sanna, M. Kavousi, S. E. Baumeister, et al. 2011. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. Nat. Genet. 43: 1131-1138.
22. Würtz, P., J. R. Raiko, C. G. Magnussen, P. Soininen, A. J. Kangas, T. Tynkkynen, R. Thomson, R. Laatikainen, M. J. Savolainen, J. Laurikka, et al. 2012. High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis. Eur. Heart J. 33: 2307-2316.
23. Brunt, E. M., C. G. Janney, A. M. Di Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon. 1999. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94: 2467-2474.
24. Kleiner, D. E., E. M. Brunt, M. Van Natta, C. Behling, M. J. Contos, O. W. Cummings, L. D. Ferrell, Y. C. Liu, M. S. Torbenson, A. Unalp-Arida, et al.; Nonalcoholic Steatohepatitis Clinical Research Network. 2005. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 41: 1313-1321.
25. Miettinen, T. A. 1988. Cholesterol metabolism during ketoconazole treatment in man. J. Lipid Res. 29: 43-51.
26. Tukiainen, T., T. Tynkkynen, V. P. Makinen, P. Jylanki, A. Kangas, J. Hokkanen, A. Vehtari, O. Grohn, M. Hallikainen, H. Soininen, et al. 2008. A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease. Biochem. Biophys. Res. Commun. 375: 356-361.
27. 1H NMR spectroscopy: constrained total-line-shape fitting. Anal. Chim. Acta. 542: 178-185.
28. Romeo, S., J. Kozlitina, C. Xing, A. Pertsemlidis, D. Cox, L. A. Pennacchio, E. Boerwinkle, J. C. Cohen, and H. H. Hobbs. 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40: 1461-1465.
29. Benjamini, Y., and Y. Hochberg. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B. 57: 289-300.
30. Min, H. K., A. Kapoor, M. Fuchs, F. Mirshahi, H. Zhou, J. Maher, J. Kellum, R. Warnick, M. J. Contos, and A. J. Sanyal. 2012. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 15: 665-674.
31. Speliotes, E. K., J. L. Butler, C. D. Palmer, B. F. Voight; GIANT Consortium; MIGen Consortium; NASH CRN; and J. N. Hirschhorn. 2010. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology. 52: 904-912.
32. Fon Tacer, K., and D. Rozman. 2011. Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation. J. Lipids. 2011: 783976.
33. McCullough, A. J. 2011. Epidemiology of the metabolic syndrome in the USA. J. Dig. Dis. 12: 333-340.
34. Corey, K. E., M. Lai, L. G. Gelrud, J. Misdraji, L. L. Barlow, H. Zheng, K. L. Andersson, M. Thiim, D. S. Pratt, and R. T. Chung. 2012. Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 10: 651-656.
35. Marí, M., F. Caballero, A. Colell, A. Morales, J. Caballeria, A. Fernandez, C. Enrich, J. C. Fernandez-Checa, and C. Garcia-Ruiz. 2006. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab. 4: 185-198.
36. Yao, P. M., and I. Tabas. 2001. Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway. J. Biol. Chem. 276: 42468-42476.
37. Van Rooyen, D. M., C. Z. Larter, W. G. Haigh, M. M. Yeh, G. Ioannou, R. Kuver, S. P. Lee, N. C. Teoh, and G. C. Farrell. 2011. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology. 141: 1393-1403.
38. Henkel, A., and R. M. Green. 2013. The unfolded protein response in fatty liver disease. Semin. Liver Dis. 33: 321-329.
39. Fujita, K., Y. Nozaki, K. Wada, M. Yoneda, Y. Fujimoto, M. Fujitake, H. Endo, H. Takahashi, M. Inamori, N. Kobayashi, et al. 2009. Dysfunctional very-low-density lipoprotein synthesis and release is a key factor in nonalcoholic steatohepatitis pathogenesis. Hepatology. 50: 772-780.
40. Caballero, F., A. Fernandez, A. M. De Lacy, J. C. Fernandez-Checa, J. Caballeria, and C. Garcia-Ruiz. 2009. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J. Hepatol. 50: 789-796.
41. Ordovas-Montanes, J. M., and J. M. Ordovas. 2012. Cholesterol, inflammasomes, and atherogenesis. Curr. Cardiovasc. Risk Rep. 6: 45-52.
42. Im, S. S., L. Yousef, C. Blaschitz, J. Z. Liu, R. A. Edwards, S. G. Young, M. Raffatellu, and T. F. Osborne. 2011. Linking lipid metabolism to the innate immune response in macrophages through sterol regulatory element binding protein-1a. Cell Metab. 13: 540-549.
43. Tice, J. A., L. Karliner, J. Walsh, A. J. Petersen, and M. D. Feldman. 2008. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am. J. Med. 121: 885-893.
44. de Almeida, S. R., P. R. Rocha, M. D. Sanches, V. H. Leite, R. A. da Silva, M. T. Diniz, F. Diniz Mde, and A. L. Rocha. 2006. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes. Surg. 16: 270-278.
45. Clark, J. M., A. R. Alkhuraishi, S. F. Solga, P. Alli, A. M. Diehl, and T. H. Magnuson. 2005. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes. Res. 13: 1180-1186.
46. Barker, K. B., N. A. Palekar, S. P. Bowers, J. E. Goldberg, J. P. Pulcini, and S. A. Harrison. 2006. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am. J. Gastroenterol. 101: 368-373.